带支架与无支架生物瓣治疗活动性主动脉瓣心内膜炎
该回顾性队列纳入1998至2017年265例活动性主动脉瓣心内膜炎行主动脉瓣置换患者,带支架瓣97例(37%),无支架瓣168例(63%)。两组手术死亡率相近(6.2%对7.1%),无支架瓣10年再手术累积发生率更低(3.4%对12%),10年免于心内膜炎复发率更高(98%对88%)。结论为对经选择患者两种瓣膜均适用。
要点
- 带支架与无支架瓣手术死亡率相近(6.2%对7.1%)。
- 无支架瓣10年再手术率更低(3.4%对12%)。
- 无支架瓣10年免于心内膜炎复发率更高(98%对88%)。
核心结论
- 对经选择的活动性主动脉瓣心内膜炎患者,带支架与无支架生物瓣均为合适的置换管道。
研究设计与样本
- 1998至2017年单中心回顾性队列,265例活动性主动脉瓣心内膜炎行主动脉瓣置换,带支架瓣97例(37%),无支架瓣168例(63%)。
- 无支架瓣中采用inclusion技术142例(85%),全根部替换26例(15%)。
- 数据来自胸外科医师学会数据库并结合病历回顾、问卷及国家死亡指数。
主要发现
- 带支架组与无支架组中位年龄分别为53岁(43-56)和57岁(44-66)。
- 带支架组与无支架组分别有高比例心衰(54%对40%)、肝病(16%对7.7%)、人工瓣心内膜炎(14%对48%)、根部脓肿(38%对70%)及同期升主动脉手术(6.2%对22%)。
- 无支架组11%需永久起搏器。
- 两组手术死亡率相近(6.2%对7.1%),5年生存率分别为52%和63%。
- 长期死亡显著危险因素包括肝病(HR 2.38)、既往心梗(HR 1.64)、充血性心衰(HR 1.63)及需透析的肾衰竭(HR 4.37)。
临床怎么用
- 对经选择的活动性主动脉瓣心内膜炎患者,带支架与无支架生物瓣均可作为瓣膜置换选择。
- 合并肝病、既往心梗、充血性心衰或需透析肾衰竭者长期死亡风险较高,需强化围术期与远期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to provide evidence for choosing a bioprosthesis in treating patients with active aortic valve endocarditis. METHODS: From 1998 to 2017, 265 patients with active aortic valve endocarditis underwent aortic valve replacement with a stented valve (n = 97, 37%) or a stentless valve (n = 168, 63%) with further breakdown into inclusion technique (n = 142, 85%) or total root replacement (n = 26, 15%). Data were obtained from the Society of Thoracic Surgeons database aided with chart review, surveys, and National Death Index data. RESULTS: The median age of patients was 53 years (43-56) in the stented group and 57 years (44-66) in the stentless group. The stented and stentless groups had high rates of heart failure (54% and 40%), liver disease (16% and 7.7%), prosthetic valve endocarditis (14% and 48%), root abscess (38% and 70%), and concomitant ascending aorta procedures (6.2% and 22%), respectively. The stentless group required permanent pacemakers in 11% of cases. Operative mortality was similar between groups (6.2% and 7.1%). The 5-year survival was 52% and 63% in the stented and stentless groups, respectively. Significant risk factors for long-term mortality included liver disease (hazard ratio, 2.38), previous myocardial infarction (hazard ratio, 1.64), congestive heart failure (hazard ratio, 1.63), and renal failure requiring dialysis (hazard ratio, 4.37). The 10-year cumulative incidence of reoperation was 12% and 3.4% for the stented and stentless groups, respectively. The 10-year freedom from reoccurrence of aortic valve endocarditis was 88% for the stented and 98% for the stentless groups. CONCLUSIONS: Both stented and stentless aortic valves are appropriate conduits for replacement of active aortic valve endocarditis for select patients.
引用
- Clemence J, Caceres J, Ren T, et al. Treatment of aortic valve endocarditis with stented or stentless valve. J Thorac Cardiovasc Surg. 2020. PMID: 32980146. doi:10.1016/j.jtcvs.2020.08.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。